TrianglePUBLICATIONS · 37879444
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2024 Jan
- First author
- Passaro A
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Passaro A
- type
- Author
- name
- Wang J
- type
- Author
- name
- Wang Y
- type
- Author
- name
- Lee SH
- type
- Author
- name
- Melosky B
- type
- Author
- name
- Shih JY
- type
- Author
- name
- Wang J
- type
- Author
- name
- Azuma K
- type
- Author
- name
- Juan-Vidal O
- type
- Author
- name
- Cobo M
- type
- Author
- name
- Felip E
- type
- Author
- name
- Girard N
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Passaro A
- type
- Author
- name
- Wang J
- type
- Author
- name
- Wang Y
- type
- Author
- name
- Lee SH
- type
- Author
- name
- Melosky B
- type
- Author
- name
- Shih JY
- type
- Author
- name
- Wang J
- type
- Author
- name
- Azuma K
- type
- Author
- name
- Juan-Vidal O
- type
- Author
- name
- Cobo M
- type
- Author
- name
- Felip E
- type
- Author
- name
- Girard N
- type
- Author
- bibliography ids
- nci-bib-c0352f44a92ec265c8950d4c
- book metadata
- content sha256
- 8c949c9c67a474fbc9433cf3798effd6edc3b30d102e8abc5252a3636215428b
- document type
- citation
- dois
- 10.1016/j.annonc.2023.10.117
- electronic publication date
- display
- 2023 Oct 23
- precision
- day
- year
- 2023
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:37879444
- immutable id
- pubmed:37879444@8c949c9c67a474fbc9433cf3798effd6edc3b30d102e8abc5252a3636215428b
- journal
- abbreviation
- Ann Oncol
- issn electronic
- 1569-8041
- issn print
- 0923-7534
- issue
- 1
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 77-90
- volume
- 35
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 37879444
- provenance
- batch id
- 6d213eecf21b6b7867cb
- provider
- NCBI PubMed ESummary
- record sha256
- c4a49960849a6fd1b4d4397eda7aefbe6550b5b69bbf431c25364d95edce050e
- response sha256
- 684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
- retrieved at
- 2026-09-09T23:48:19.049083+00:00
- publication date
- display
- 2024 Jan
- precision
- month
- year
- 2024
- publication types
- Clinical Trial, Phase III
- Journal Article
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Preserved source evidence · Not medical advice